Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of levofloxacin丨cas 100986-85-4 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
| Grade: | USP43 |
| Appearance: | Light yellowish-White to Yellow-White crystals or crystalline Powder |
| Assay (on the anhydrous basis): | 98.0%~102.0% of C18H20FN3O4 |
| Identification: | (1) IR (2) HPLC |
| Water: | 2.0%~3.0% |
| Optical rotation: | -92~-106° |
| Residue on ignition: | 0.2% max |
| Procedure 1 (by HPLC) | |
| N-Desmethyl levofloxacin: | 0.3% max |
| Diamine derivative: | 0.3% max |
| Levofloxacin N-oxide: | 0.3% max |
| 9-Desfluoro levofloxacin: | 0.3% max |
| D-Isomer: | 0.8% max |
| Any unknown impurity: | 0.1% max |
| Total impurity (excluding D-Isomer): | 0.5% max |
| Procedure 2 (by HPLC) | |
| Levofloxacin related compound A (N-Desmethyl levofloxacin): | 0.2% max |
| Levofloxacin related compound B: | 0.13% max |
| Any other impurity: | 0.10% max |
| Total impurities: | 0.5% max |
| Residual solvents | |
| Chloroform: | 60 ppm max |
| Ethanol: | 1000 ppm max |
| DMSO: | 1000 ppm max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2941909099999 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Tightly closed. Store in a closed, dry, ventilated place |
|
Condition to Avoid |
Strong oxidizing agents |
|
Package |
Manufacturing Information
|
Parameter |
Specification |
|
Capacity |
10MT/month |
|
Frequency |
|
|
Main Export Countries |
|
|
Capacity/Batch |
|
|
Experience |
Production since 2007 |
|
Stock |
Applications
1. Respiratory Tract Infections
Levofloxacin is a first-line treatment for:
Community-acquired pneumonia (CAP)
Acute bacterial sinusitis
Acute exacerbation of chronic bronchitis
Its excellent tissue penetration and long half-life make it particularly effective in treating deep respiratory infections.
2. Urinary Tract Infections (UTIs)
Used for both complicated and uncomplicated UTIs, including pyelonephritis.
Also effective for prostatitis caused by susceptible bacterial strains.
3. Skin and Soft Tissue Infections
Treats infections like cellulitis, abscesses, and infected wounds.
4. Gastrointestinal and Intra-abdominal Infections
Sometimes used in combination therapies to treat bacterial gastroenteritis and intra-abdominal sepsis.
5. Ophthalmic Use
Available as eye drops for treating bacterial conjunctivitis, keratitis, and other ocular infections.
6. Ear, Nose, and Throat (ENT) Infections
Effective in treating otitis media, pharyngitis, and tonsillitis in select cases.
7. Tuberculosis (MDR-TB and XDR-TB)
Used as a second-line drug in multi-drug resistant tuberculosis regimens.
8. Anthrax (Post-Exposure Prophylaxis)
Approved for inhalation anthrax exposure due to its activity against Bacillus anthracis.
Benefits
1. Broad-Spectrum Antibacterial Activity
Covers a wide range of pathogens, including:
Gram-negative bacteria: E. coli, Klebsiella, Pseudomonas aeruginosa
Gram-positive bacteria: Streptococcus pneumoniae, Staphylococcus aureus
Atypical organisms: Mycoplasma, Chlamydia, Legionella
2. Excellent Bioavailability
Almost 100% oral bioavailability - oral and IV doses are typically interchangeable, improving outpatient treatment options.
3. Long Half-Life
Allows once-daily dosing, improving patient compliance.
4. High Tissue Penetration
Penetrates well into lungs, sinuses, kidneys, prostate, and soft tissues, making it highly effective for deep-seated infections.
5. Well-Studied and Approved Globally
FDA-approved and widely prescribed in both hospital and outpatient settings.
Conclusion
Levofloxacin (CAS 100986-85-4) remains a powerful and versatile antibiotic, valued for its broad-spectrum coverage, high bioavailability, and convenient dosing schedule. When used responsibly, it plays a critical role in the management of serious infections in both inpatient and outpatient care. However, attention must be given to antibiotic stewardship and monitoring for side effects, especially in vulnerable populations.

